Phase III Study Results Of Halaven® (eribulin mesylate) Injection In Metastatic Breast Cancer Presented At SABCS

     Phase III Study Results Of Halaven® (eribulin mesylate) Injection In
                 Metastatic Breast Cancer Presented At SABCS

PR Newswire

SAN ANTONIO, Dec. 7, 2012

SAN ANTONIO, Dec.7, 2012 /PRNewswire/ --Results from the first large, global
Phase III study of Halaven^® (eribulin mesylate) Injection in patients with
early-stage metastatic breast cancer were presented today during the 2012
CTRC-AACR San Antonio Breast Cancer Symposium.

(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO )

The 1,102-patient, open-label, multi-center study compared Halaven versus
capecitabine (Xeloda^®) in women with locally advanced or metastatic breast
cancer. The majority of the patients received study treatment as their first
or second-line chemotherapy for metastatic disease, a different population
than what was studied for FDA approval.

The study did not meet the co-primary endpoints for overall survival or
progression-free survival. However, the data showed a trend toward improved
overall survival in patients treated with Halaven with a median survival of
15.9 months versus 14.5 months with capecitabine (HR 0.879; 95% CI 0.770,
1.003; p=0.056). Progression-free survival was 4.1 and 4.2 months for eribulin
and capecitabine, respectively (independent review; HR 1.079; 95% CI 0.932,
1.250; p=0.305).

Additionally, pre-specified exploratory subgroup analyses suggested a
potential overall survival advantage for Halaven over capecitabine in certain
patient populations based on receptor status. Further study is warranted.

Adverse events (AEs) were consistent with the known side-effect profiles of
both drugs. The most common AEs for eribulin and capecitabine (> 20% all
grades) were neutropenia (54.2% vs. 15.9%), hand-foot syndrome (0.2% vs.
45.1%), alopecia (34.6% vs. 4.0%), leukopenia (31.4% vs. 10.4%), diarrhea
(14.3 vs. 28.8%) and nausea (22.2% vs. 24.4%), respectively.

"Though the study did not reach the statistical threshold required to prove
superiority compared to capecitabine – a commonly used treatment in earlier
lines of metastatic breast cancer – trends observed in certain patient
populations that were treated with Halaven merit additional research,
especially considering the unmet need in metastatic breast cancer," said Peter
A. Kaufman, MD, one of the lead investigators of the study and Associate
Professor of Medicine, Geisel School of Medicine at Dartmouth and an
oncologist and hematologist at the Norris Cotton Cancer Center in Lebanon, New
Hampshire.

About the Study
Study 301 was a global, open-labeled, randomized, two-parallel-arm,
multi-center study of Halaven (eribulin mesylate) Injection versus
capecitabine in 1,102 women with locally advanced or metastatic breast cancer
previously treated with anthracyclines and taxanes, either in the (neo)
adjuvant setting or for locally advanced or metastatic disease. Patients in
the study received zero to two previous chemotherapies for advanced disease.

Patients were randomized to treatment with either Halaven 1.4mg/m^2
(administered intravenously over two to five minutes on days 1 and 8, every 21
days) or capecitabine 2.5g/m^2 (administered orally twice daily in two equal
doses on days 1 to 14, every 21 days).

About Halaven
Halaven is indicated for the treatment of patients with metastatic breast
cancer who have previously received at least two chemotherapeutic regimens for
the treatment of metastatic disease. Prior therapy should have included an
anthracycline and a taxane either in the adjuvant or metastatic setting.

Important Safety Information

Decreased White Blood Cells (Neutropenia)
A doctor should do a blood test to monitor a patient's blood cells before they
receive each dose of Halaven, and should monitor them more often if they
develop lower white blood cells. If a patient develops severe neutropenia
lasting longer than 7 days or neutropenia with a fever, their next dose of
Halaven should be delayed and reduced. Severe neutropenia occurred in 57%
(287/503) of patients who received Halaven and lasted more than 1 week in 12%
(62/503) of patients. Neutropenia with a fever occurred in 5% (23/503) of
patients; 2 patients died from complications of neutropenia with a fever.
Neutropenia with a fever can result in serious infections that could lead to
hospitalization or death. Patients should call their healthcare provider
immediately if they have any of the following symptoms; fever (temperature
above 100.5degrees F), chills, coughing, burning or pain when they urinate.

Nerve Disorders (Peripheral Neuropathy)
Halaven can cause numbness, tingling, or burning in a patient's hands and feet
(peripheral neuropathy). A patient should be monitored closely for signs of
neuropathy. If a patient develops severe neuropathy, treatment with Halaven
should be delayed until the neuropathy improves and the next dose of Halaven
should be reduced. Severe peripheral neuropathy occurred in 8% (42/503) of
patients who received Halaven. Neuropathy lasting more than one year occurred
in 5% of patients. Twenty-two percent (109/503) of patients developed a new or
worsening neuropathy that had not recovered after an average of 269 days.
Peripheral neuropathy was the most common side effect that caused patients to
stop receiving Halaven.

Pregnancy and Nursing
Halaven may harm a patient's unborn baby. A patient should avoid becoming
pregnant while they are receiving Halaven. A patient should tell their
healthcare provider right away if they become pregnant or think they are
pregnant while they are receiving Halaven. The patient and their healthcare
provider should decide if they will receive Halaven or breastfeed. A patient
should not do both.

Heartbeat Changes
Halaven can cause changes in a patient's heartbeat (called QTc prolongation).
This can cause irregular heartbeats that may lead to death. A patient's
healthcare provider will decide if they need heart monitoring
(electrocardiogram or ECG), or blood tests during their treatment with Halaven
to watch for this problem.

Liver and Kidney Problems
In patients with mild or moderate liver problems, and/or moderate kidney
problems, a lower starting dose of Halaven is recommended.

Most Common Side Effects
The most common side effects reported in >25% of patients receiving Halaven
were low white blood cells (82%), low red blood cells (58%),
weakness/tiredness (54%), hair loss (45%), numbness, tingling or burning in
your hands and feet (35%), nausea (35%), and constipation (25%). The most
common serious side effects reported in patients receiving Halaven were
neutropenia with or without a fever (4% and 2%, respectively).

For full prescribing information for HALAVEN, please visit:
http://www.halaven.com/sites/default/files/HALAVEN_full_Prescribing_Information.pdf

Eisai Oncology
Eisai Oncology is dedicated to discovering, developing and producing
innovative oncology therapies that can help make a difference and impact the
lives of patients and their families. This passion for people is part of
Eisai's human health care (hhc) mission, which is to help address unmet
medical needs and to increase the benefits health care provides to patients
and their families. Our commitment to meaningful progress in oncology
research, built on scientific expertise, is supported by a global capability
to conduct discovery and preclinical research, and develop small molecules,
biologic and supportive care agents for cancer across multiple indications.

Eisai Inc.
Eisai Inc. was established in 1995 and began marketing its first product in
the United States in 1997. Since that time, Eisai Inc. has rapidly grown to
become a fully integrated pharmaceutical business. Eisai's key areas of
commercial focus are neurology and oncology. The company serves as the U.S.
pharmaceutical operation of Eisai Co., Ltd., a research-based human health
care (hhc) company that discovers, develops and markets products throughout
the world.

Eisai has a global product creation organization that includes U.S.-based R&D
facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as
well as manufacturing facilities in Maryland and North Carolina. The company's
areas of R&D focus include neuroscience; oncology; vascular, inflammatory and
immunological reaction; and antibody-based programs. For more information
about Eisai, please visit www.eisai.com/US.

Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that
discovers, develops and markets products throughout the world. Through a
global network of research facilities, manufacturing sites and marketing
subsidiaries, Eisai actively participates in all aspects of the worldwide
healthcare system.

Media Inquiries                       Investor Inquiries
Laurie Landau                         Alex Scott
Eisai Inc.                            Eisai Inc.
During SABCS: 973-493-7971 201-746-2177
201-746-2510 (office)

SOURCE Eisai Inc.

Website: http://www.eisai.com